Scotia Capital Inc. Buys Shares of 10,652 Henry Schein, Inc. (NASDAQ:HSIC)

Scotia Capital Inc. acquired a new position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 10,652 shares of the company's stock, valued at approximately $737,000.

Several other large investors have also recently bought and sold shares of HSIC. Invesco Ltd. raised its position in shares of Henry Schein by 0.4% during the fourth quarter. Invesco Ltd. now owns 4,963,409 shares of the company's stock worth $343,468,000 after acquiring an additional 17,552 shares during the last quarter. FMR LLC lifted its position in Henry Schein by 6.6% during the 4th quarter. FMR LLC now owns 3,498,033 shares of the company's stock valued at $242,064,000 after purchasing an additional 217,143 shares during the period. Geode Capital Management LLC boosted its stake in shares of Henry Schein by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 3,169,033 shares of the company's stock valued at $218,762,000 after purchasing an additional 14,876 shares during the last quarter. Lyrical Asset Management LP acquired a new stake in shares of Henry Schein during the 4th quarter worth approximately $126,655,000. Finally, Clarkston Capital Partners LLC raised its stake in shares of Henry Schein by 24.8% during the fourth quarter. Clarkston Capital Partners LLC now owns 1,744,225 shares of the company's stock worth $120,700,000 after buying an additional 346,420 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company's stock.

Insider Activity at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the sale, the chief executive officer now owns 62,688 shares in the company, valued at approximately $4,460,251.20. This represents a 6.05 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the sale, the director now owns 24,805 shares in the company, valued at approximately $1,762,147.20. The trade was a 9.50 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Henry Schein Trading Up 2.3 %

NASDAQ:HSIC traded up $1.44 during trading hours on Friday, reaching $64.73. The company's stock had a trading volume of 1,390,004 shares, compared to its average volume of 1,616,977. The firm has a market capitalization of $7.93 billion, a price-to-earnings ratio of 26.64, a PEG ratio of 2.13 and a beta of 0.84. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $82.49. The firm has a 50-day simple moving average of $70.41 and a 200-day simple moving average of $71.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the prior year, the business posted $0.66 earnings per share. Henry Schein's quarterly revenue was up 5.8% compared to the same quarter last year. Research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. UBS Group lowered their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. Wells Fargo & Company started coverage on shares of Henry Schein in a research note on Friday, February 14th. They issued an "equal weight" rating and a $80.00 target price for the company. Jefferies Financial Group boosted their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a research report on Thursday, January 23rd. Bank of America raised Henry Schein from an "underperform" rating to a "buy" rating and increased their price target for the company from $69.00 to $84.00 in a research report on Monday, January 6th. Finally, StockNews.com lowered shares of Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Henry Schein currently has an average rating of "Moderate Buy" and a consensus target price of $81.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.